The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
== Writers == Clement Clarke Moore (1798), purported author of A Visit From St. Nicholas Robert Charles Sands (1815), poet and writer Charles Fenno Hoffman (1825), poet, translator, and editor, founder of The Knickerbocker magazine Cornelius Mathews* (1834), writer of the Young America movement Evert Augustus Duyckinck (1835), literary biographer in the Young America movement George Templeton Strong (1838), noted diarist; founder of the United States Sanitary Commission and the Union League Club of New York Edgar Fawcett (1867), novelist William Dudley Foulke (1869), literary critic, journalist, and reformer; former United States Civil Service Commission commissioner Duffield Osborne (1879), author John Kendrick Bangs (1883), author, satirist, editor of Puck magazine John Armstrong Chaloner (1883), writer and activist, brother of Lewis Stuyvesant Chanler and William A.
== History == In the United States, the profession began in the 1950s due to a shortage of medical technologists in rural areas and physician owned laboratories. MLA positions were more prevalent prior to laboratory automation, but have made a comeback due to the ongoing laboratory staffing shortage.
In RNA molecules, the DNA base thymine is replaced by uracil which is able to base pair with adenine. Therefore, in the pre-mRNA molecule, all complementary bases which would be thymine in the coding DNA strand are replaced by uracil.
== Further reading == Farlow, J. O.; Gatesy, S. M.; Holtz, T. R. Jr.; Hutchinson, J. R.; Robinson, J. M. (2000). "Theropod Locomotion". American Zoologist. 40 (4): 640–663. doi:10.1093/icb/40.4.640. JSTOR 3884284.
==== Comparison of pharmacokinetics between dosage forms ==== The free acid (HMB-FA) and monohydrated calcium salt (HMB-Ca) forms of HMB have different pharmacokinetics. HMB-FA is more readily absorbed into the bloodstream and has a longer elimination half-life (3 hours) relative to HMB-Ca (2.5 hours). Tissue uptake and utilization of HMB-FA is 25–40% higher than for HMB-Ca. The fraction of an ingested dose that is excreted in urine does not differ between the two forms.
Sources: en.wikipedia.org
=== Main === Ben Feldman as Avi Schwooper, the oldest of the Schwooper children. Born in 1982 and growing up in Mountain View, California with his siblings, Avi has extensive knowledge of pop culture and music; he works as a review columnist and, by 2021, for a music streaming service. Avi is grounded and witty, but also cynical and passive in conflict. Avi starts dating Jen in 2004, and they later marry and have a daughter named Hannah, residing in Santa Rosa, California. By the 2010s, their relationship begins to break down, and they divorce in 2020, sharing custody of the now-teenage Hannah. In his adult years, Avi distances himself from his Jewish religious heritage, and is shown to be unable to tell his family he loves them, rather saying "Hey…y’know?" to indicate it. Avi suffers from pattern hair loss. Angelique Cabral as Jen Schwooper, Avi's non-Jewish girlfriend and later wife, born in 1983. Jen and Avi divorced in 2020, due to Naomi's passive aggression toward her and undermining her, and Avi's parenting. Avi struggled to stand up for himself and others and was cynical, and they grew apart. Jen majored in acting, but after the stress of putting on several failed plays in New York with her friends, Jen secretly wishes for a more regular job. Jen agrees to move to California after Avi is offered a music-journalism internship, though it is hinted she is ashamed she gave up acting. While it’s implied she helps with the theatre at Hannah's school in 2014, by 2019 Jen becomes a lucrative wine salesperson.
Knudsen's team, specifically Jesper Lau and Thomas Kruse, then worked on what became semaglutide, which had greater stability and affinity to albumin, lengthening its duration of action further to a once-weekly drug. Semaglutide was approved in the United States under the brand name Ozempic as a treatment for type 2 diabetes in 2017, and under the brand name Wegovy, as a first injectable (at 2.4 mg once weekly), for chronic weight management in June 2021. In January 2025, the FDA approved a pill form of Wegovy with doses ranging from 1.5 mg to 25 mg.
== Children == A child's exposure to contaminants in the air can have detrimental health effects including heightened risk of respiratory tract infections, increased likelihood of childhood asthma, behavioural problems and reduced neurocognitive abilities. Exposure to mainstream and sidestream smoke in childhood poses an increased risk of coughing, wheezing, and mucus production. Studies on rats have shown that those who were exposed to sidestream smoke while in utero and following the period directly after, had differences in airway sensitivity in comparison to those that had been exposed to sidestream smoke only while in utero or only following the period after.
==== Investigation of Bruno Pacheco ==== On 16 November 2021, leaked chats showed that then presidential secretary Bruno Pacheco attempted to pressure the SUNAT to favor certain companies and individuals. On 19 November 2021, Bruno Pacheco resigned as presidential secretary due to his role in the Walter Ayala controversy, regarding attempts to irregularly promote military personnel. Pacheco maintained that he was resigning in order to stop the smear campaign against the President. His position was replaced by Carlos Jaico. On 23 November 2021, the Public Prosecutor's Office found $20,000 in cash inside Pacheco's office bathroom in the Governmental Palace. Pacheco claimed that this money came from his savings and the salary he received. On 24 November 2021, Alejandro Aguinaga, a Popular Force parliamentarian and president of the Congressional Oversight Commission called on Prime Minister Mirtha Vásquez to indicate what measures would be taken against Pacheco. In response, the Free Peru parliamentarian Guillermo Bermejo accused the Fujimorist Popular Force of double standards and brought up corruption charges against Alberto Fujimori and Vladimiro Montesinos. Meanwhile, the former prime minister Guido Bellido said "It makes me suspicious that someone goes to work with his 20 thousand dollars," and stated that it would be evaluated and taken into account in Free Peru's stance on the impeachment motion.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.